LienTeh.net > Ads > Bolemide (Pomalidomide) 4mg

Bolemide (Pomalidomide) 4mg

Inquire / Price

Model Number：

RL1420230901129
Brand Name：

Bolemide
Origin：

Generic drug, LAOS.
Small Orders：

Small order has available
Tags：

Multiple Myeloma

Inquire Now Link

Poster

Details
Description

Packaging Size

4mg*21capsules/box
Strength

4mg
Compositon

Pomadonitmite
Treatment

multiple myeloma
Form

Capsule
Brand

Bolemide
Quantity Unit

21capsules/box
Manufacturer

Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）

Contents hide

1 Indication

2 Dosage and Administration 1. Administration

3 Warnings and Precautions

4 Adverse reactions

5 Storage method

Indication

Bolemide (Permalidomide) is a thalidomide analog in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies , including lenalidomide and a proteasome inhibitor , and who have been Disease progression was confirmed within 60 days of completion of the last treatment .

Dosage and Administration
1. Administration

Multiple myeloma : pomalidomide 4 mg orally per day on days 1-21 of a cycle of 28 days ;

In combination with 40 mg daily on days 1 , 8 , 15, and 22 of each cycle ; more than

For 75-year-olds, the initial dose of dexamethasone is daily on days 1 , 8, 15, and 22 of each cycle.

2 0mg each time. Cycles are repeated until disease progression or toxicity is not tolerated.

2. Dosage Form Specifications

● Capsules, 2 mg, 3 mg, 4 mg. 3. Contraindications: Pregnant women are prohibited .

Warnings and Precautions

● Hematologic toxicity : The most common grade 3/4 adverse event was neutropenia . Monitor patients for hematologic toxicity , especially neutropenia .

• Hepatotoxicity: Liver failure including fatal events; monitor liver function tests monthly .

● Hypersensitivity reactions : Angioedema and severe dermatological reactions have been reported . vascular water

Swelling and severe dermatological reactions discontinue pomalidomide therapy .

Tumor lysis syndrome (TLS ) : monitor patients at risk for TLS (eg , patients with high tumor burden)

) and take appropriate precautions .

Adverse reactions

Most common adverse reactions ( ≥ 30%) : fatigue, asthenia , neutropenia , anemia , constipation , nausea , diarrhea , dyspnea, upper respiratory tract infection , back pain and fever.